In this continuing Bioengineering Research Partnership project, we seek to design improved antibody drugs for blocking aberrant signaling by epidermal growth factor receptor (EGFR) in cancer. A team with expertise in protein engineering (Wittrup, MIT), structural biology (Kuriyan, UC Berkeley), cell engineering (Lauffenburger, MIT), proteomics (White, MIT), and medical imaging (Larson, MSKCC) will further develop and characterize a panel of anti-EGFR molecules isolated in the previous project period. Our central hypothesis is that antibodies binding to domain IV of EGFR (anti-IV) block signaling in a ligand-independent manner, enabling antagonism of a common truncation mutant (EGFRvlll) that is not antagonized by the current generation of anti-EGFR antibodies. Anti-IV antibodies and fluorescence-based biophysical techniques will be used to further study the transduction of a symmetric ligand-bound extracellular dimerization event to an asymmetric active kinase dimer in the cytoplasm, recently characterized as part of this project. The molecular allosteric mechanisms that result in kinase domain activation upon ligand binding will be delineated so as to understand better how to block this process. We will apply mass spectrometry to simultaneously quantify the phosphorylation kinetics of hundreds of specific tyrosines in the signaling pathways downstream of EGFR, in particular looking for proximal evidence for eradication of EGFRvlll's effects by anti-IV antibodies. Enhanced receptor downregulation with multivalent antibodies will be systematically studied and exploited to reduce receptor number. Effects of anti-IV antibodies on migration and proliferation will be examined in autocrine cell lines. The kinetics of antibody penetration into tumor spheroids will be studied by 2-photon microscopy. In mouse xenograft models, the pharmacokinetics and pharmacodynamics of these antibodies will be studied by PET. This project is a systematic effort by a team of engineers, scientists, and physicians to develop a new generation of anticancer drugs through improved mechanistic understanding and blocking of a common class of uncontrolled growth signals sent by receptors on the surface of cancer cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ONC-G (03))
Program Officer
Welch, Anthony R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts Institute of Technology
Engineering (All Types)
Schools of Engineering
United States
Zip Code
Van Deventer, James A; Wittrup, Karl Dane (2014) Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation. Methods Mol Biol 1131:151-81
Engel, Kate; Sasaki, Tomoaki; Wang, Qi et al. (2013) A highly efficient peptide substrate for EGFR activates the kinase by inducing aggregation. Biochem J 453:337-44
Arkhipov, Anton; Shan, Yibing; Das, Rahul et al. (2013) Architecture and membrane interactions of the EGF receptor. Cell 152:557-69
Wagner, Joel P; Wolf-Yadlin, Alejandro; Sevecka, Mark et al. (2013) Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal 6:ra58
Endres, Nicholas F; Das, Rahul; Smith, Adam W et al. (2013) Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152:543-56
Dang, Michelle; Armbruster, Nicole; Miller, Miles A et al. (2013) Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways. Proc Natl Acad Sci U S A 110:9776-81
Hackel, Benjamin J; Neil, Jason R; White, Forest M et al. (2012) Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel 25:47-57
Swers, Jeffrey S; Yeung, Yik A; Wittrup, K Dane (2011) Integrated mimicry of B cell antibody mutagenesis using yeast homologous recombination. Mol Biotechnol 47:57-69
Pirie, Christopher M; Hackel, Benjamin J; Rosenblum, Michael G et al. (2011) Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 286:4165-72
Jura, Natalia; Zhang, Xuewu; Endres, Nicholas F et al. (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42:9-22

Showing the most recent 10 out of 68 publications